CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021
October 13 2021 - 9:00AM
CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company
developing mitochondria based therapeutics to treat chronic
diseases and extend healthy lifespan, today announced that data
from its CB4211 Phase 1a/1b clinical study have been selected for
presentation during the late-breaking poster session at The
American Association for the Study of Liver Diseases (AASLD) Annual
Meeting (The Liver Meeting® 2021). This event will be held
virtually on November 12 – 15, 2021.
The presentation will discuss further details
from the Phase 1a/1b clinical study of CB4211 in obese subjects
with nonalcoholic fatty liver disease (NAFLD). In August 2021, the
company announced positive topline data from the trial, including
statistically significant reductions in ALT, AST and glucose
compared to placebo after 4 weeks of treatment with CB4211. CB4211
is under development for the treatment of nonalcoholic
steatohepatitis (NASH) and obesity. The poster will be presented by
Dr. Rohit Loomba, MD, MHSc, Professor of Medicine, Director, NAFLD
Research Center, and Director of Hepatology, University of
California at San Diego.
Presentation
InformationPublication Number:
LP5Session: Late-Breaking Abstract
PostersTitle: CB4211, a Novel Analog of MOTS-c,
Improves Markers of Liver Injury and Metabolism in Obese Subjects
with Nonalcoholic Fatty Liver Disease: A Multicenter, Double-Blind,
Randomized, Placebo-Controlled Study.
Abstracts will be available on the AASLD website
on November 1st, 2021. Details of the late-breaking abstracts will
be presented in November and published in the December issue of
Hepatology. CohBar’s poster presentation from The Liver Meeting®
2021 will be available on the company’s website following its
disclosure at the meeting. The Liver Meeting® is the premiere event
for research on new therapeutics for NASH and bringing together
clinicians, associates, and scientists from around the world to
exchange information on the latest research, discuss new
developments in liver treatment and transplantation, and network
with leading experts in the field of hepatology.
About CB4211
CB4211, discovered by CohBar scientists, is a
first-in-class mitochondria based therapeutic (MBT) under
development for the treatment of nonalcoholic steatohepatitis
(NASH) and obesity. CB4211 recently demonstrated positive effects
on reducing biomarkers of liver injury and improving metabolic
homeostasis in a Phase 1a/1b clinical study in obese subjects with
nonalcoholic fatty liver disease (NAFLD). CB4211 is a novel and
improved analog of MOTS-c, a naturally occurring mitochondrial
derived peptide (MDP). MOTS-c was discovered in 2012 by CohBar
founder Dr. Pinchas Cohen and his academic collaborators and has
been shown to play a significant role in the regulation of
metabolism in animal models. NASH has been estimated to affect as
many as 30 million adults in the U.S., and there is currently no
approved treatment for the disease.
About CohBar
CohBar (NASDAQ: CWBR) is a clinical stage
biotechnology company focused on the research and development of
mitochondria based therapeutics, an emerging class of drugs for the
treatment of chronic and age-related diseases. Mitochondria based
therapeutics originate from the discovery by CohBar’s founders of a
novel group of naturally occurring peptide sequences within the
mitochondrial genome, some of which have been shown to have the
potential to regulate key processes in multiple systems and organs
in the body. To date, the company has discovered more than 100
mitochondrial derived peptides and generated over 1,000 analogs.
CohBar’s efforts focus on the development of these peptides into
therapeutics that offer the potential to address a broad range of
diseases associated with the underlying impact of mitochondrial
dysfunction. The company’s lead compound, CB4211, which is under
development for the treatment of NASH and obesity, recently
completed a successful Phase 1a/1b clinical trial. In addition,
CohBar has four preclinical programs, the most advanced of which is
CB5138-3, a peptide with broad anti-fibrotic and anti-inflammatory
properties. This program is currently in IND-enabling studies with
the goal of filing an IND and initiating a First-in-Human study in
2022 with an initial indication of idiopathic pulmonary fibrosis.
The company also has a program in ARDS, including COVID-19
associated ARDS, as well as two peptide families with potential
utility in treating various forms of cancer.
For additional company information, please visit
www.cohbar.com.
Forward-Looking Statements
This news release contains forward-looking
statements that are not historical facts within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and
strategies, projections, anticipated events and other future
conditions. In some cases you can identify these statements by
forward-looking words such as “believe,” “may,” “will,” “estimate,”
“continue,” “anticipate,” “intend,” “could,” “should,” “would,”
“project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or
the negative or plural of these words or similar expressions.
Examples of such forward-looking statements include but are not
limited to statements regarding timing and anticipated outcomes of
research and clinical trials for our mitochondria based therapeutic
(MBT) candidates; expectations regarding the growth of MBTs as a
significant future class of drug products; and statements regarding
anticipated therapeutic properties and potential of our
mitochondrial peptide analogs, MBTs and other potential therapies.
You are cautioned that such statements are not guarantees of future
performance and that actual results or developments may differ
materially from those set forth in these forward-looking
statements. Factors that could cause actual results to differ
materially from these forward-looking statements include: our
ability to successfully advance drug discovery and development
programs, including the delay or termination of ongoing clinical
trials and the timing of announcements and updates relating to our
clinical trials and related data; our possible inability to
mitigate the prevalence and/or persistence of the injection site
reactions, receipt of unfavorable feedback from regulators
regarding the safety or tolerability of CB4211 or the possibility
of other developments affecting the viability of CB4211 or CB5138-3
as a clinical candidate or its commercial potential; results that
are different from earlier data results including less favorable
results that may not support further clinical development; our
ability to raise additional capital when necessary to continue our
operations; our ability to recruit and retain key management and
scientific personnel; the risk that our intellectual property may
not be adequately protected; our ability to establish and maintain
partnerships with corporate and industry partners; and risks
related to the impact on our business of the COVID-19 pandemic or
similar public health crises. Additional assumptions, risks and
uncertainties are described in detail in our registration
statements, reports and other filings with the Securities and
Exchange Commission and applicable Canadian securities regulators,
which are available on our website, and at www.sec.gov or
www.sedar.com. You are cautioned that such statements are not
guarantees of future performance and that our actual results may
differ materially from those set forth in the forward-looking
statements. The forward-looking statements and other information
contained in this news release are made as of the date hereof and
CohBar does not undertake any obligation to update publicly or
revise any forward-looking statements or information, whether as a
result of new information, future events or otherwise, unless so
required by applicable securities laws. Nothing herein shall
constitute an offer to sell or the solicitation of an offer to buy
any securities.
Contacts:
Jordyn TaraziDirector of Investor RelationsCohBar, Inc.(650)
445-4441Jordyn.tarazi@cohbar.com
Media:Nancy ThompsonVorticom, Inc.(212)
532-2208Nancyt@vorticom.com
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
CohBar (NASDAQ:CWBR)
Historical Stock Chart
From Jul 2023 to Jul 2024